Bioventus Inc.
BVS · NASDAQ
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $139 | $148 | $124 | $154 |
| % Growth | -6.1% | 19.2% | -19.4% | – |
| Cost of Goods Sold | $46 | $46 | $41 | $51 |
| Gross Profit | $93 | $102 | $83 | $103 |
| % Margin | 67% | 69.1% | 67% | 66.8% |
| R&D Expenses | $3 | $3 | $3 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $78 | $79 | $74 | $87 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $2 | $5 |
| Operating Expenses | $81 | $84 | $78 | $95 |
| Operating Income | $12 | $18 | $5 | $8 |
| % Margin | 8.7% | 12.4% | 3.9% | 5.2% |
| Other Income/Exp. Net | -$7 | -$8 | -$8 | -$8 |
| Pre-Tax Income | $5 | $10 | -$3 | $0 |
| Tax Expense | $1 | $1 | -$0 | $1 |
| Net Income | $3 | $7 | -$3 | -$0 |
| % Margin | 2.3% | 5.1% | -2.1% | -0.1% |
| EPS | 0.047 | 0.11 | -0.04 | -0.002 |
| % Growth | -57.2% | 375% | -1,900% | – |
| EPS Diluted | 0.046 | 0.11 | -0.04 | -0.002 |
| Weighted Avg Shares Out | 67 | 67 | 66 | 65 |
| Weighted Avg Shares Out Dil | 69 | 69 | 66 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6 | $7 | $8 | $9 |
| Depreciation & Amortization | $11 | $12 | $12 | $12 |
| EBITDA | $22 | $30 | $16 | $22 |
| % Margin | 16% | 20.2% | 12.9% | 14.1% |